Elevara raises $70M to test a breast cancer approach in rheumatoid arthritis

A London-based biotech has secured $70 million to study its CDK4/6 inhibitor — a mechanism primarily used to treat breast cancer — in rheumatoid arthritis. Elevara Medicines emerged from stealth on Tuesday with the Series A raise ...